-
CA800-PR Targets Progesterone Signaling in Breast Cancer
2026-09-09
The reference study introduces CA800-PR, a water-soluble heptamethine cyanine dye that combines tumor targeting, near-infrared imaging, and antitumor activity in hormone receptor-positive breast cancer models. Its most distinctive finding is that CA800-PR induces Golgi fragmentation, selectively reduces progesterone receptor protein expression, promotes apoptosis, and is associated with an inflammatory macrophage response.
-
Metformin Hydrochloride for AMPK Fibrosis Studies
2026-09-09
Use Metformin Hydrochloride (Metformin HCl) to connect metabolic regulation with experimentally testable antifibrotic biology. This guide translates AMPK-focused cell and rabbit workflows into practical dosing, assay, control, and troubleshooting decisions.
-
Golgi-Tracker Green Live-Cell Imaging Workflow
2026-09-08
Build a reproducible live-cell Golgi imaging workflow with a BODIPY FL-labeled C5-ceramide probe designed for membrane-selective labeling, photostability, and dynamic experiments. This guide connects organelle morphology, lipid transport, and sphingolipid metabolism analysis while showing how to interpret Golgi stress without overextending imaging data into therapeutic claims.
-
Brefeldin A Workflows for ER Stress and Cancer
2026-09-08
Brefeldin A turns a defined ER-to-Golgi trafficking block into a practical system for studying secretion, ER stress, and apoptosis. This guide connects dose and time-course design with UBR1/UBR2-centered quality-control assays, colorectal cancer research, and breast cancer cell migration inhibition.
-
740 Y-P in PI3K–Mitophagy Assays
2026-09-07
740 Y-P is a PI 3-kinase activator that can do more than elevate AKT phosphorylation: it can test whether PI3K signaling causally controls mitophagy and pyroptosis. This guide translates recent chondrocyte research into rigorous assay design, interpretation, and handling decisions.
-
TG003 for Clk and Alternative Splicing Research
2026-09-07
TG003 is a practical Cdc2-like kinase inhibitor for connecting serine/arginine-rich protein phosphorylation with measurable splice-site outcomes. Its workflow also supports mechanistic studies of CLK2-linked platinum resistance, while potency and CK1 activity require careful interpretation of concentration-dependent results.
-
GANT61 Workflow for GLI-Driven Cancer Research
2026-09-05
GANT61 is a practical GLI inhibitor for separating terminal Hedgehog pathway control from upstream signaling effects. This workflow covers solvent handling, transcriptional assays, immune-microenvironment extensions, xenograft planning, and troubleshooting for reproducible cancer research.
-
Toremifene for Breast Cancer: 20 Years of Evidence
2026-09-04
This review synthesizes two decades of clinical experience with toremifene and clarifies its position among endocrine treatments for estrogen receptor–positive breast cancer. Its main contribution is a clinically focused comparison of efficacy, safety, pharmacokinetics, CYP2D6-related metabolism, and the practical differences between selective estrogen receptor modulation and aromatase inhibition.
-
4-Ethylphenyl Sulfate: Matrix-Aware Research
2026-09-04
Explore 4-ethylphenyl sulfate as a matrix-sensitive research tool spanning renal dysfunction biomarker studies and gut microbiota-brain interaction research. This guide connects chemical handling, protein adsorption, assay design, and interpretation across renal and neurobehavioral models.
-
Golgi-Tracker Green: From Signal to Mechanism
2026-09-03
Golgi-Tracker Green enables selective live-cell Golgi apparatus labeling with a BODIPY FL-labeled C5-ceramide design. This article explains how to convert Golgi fluorescence into rigorous readouts of membrane organization, lipid transport, and cancer-cell stress while avoiding unsupported mechanistic conclusions.
-
L-Phenylephrine: A Better Baroreflex Probe
2026-09-03
L-Phenylephrine is an adrenergic α1A receptor agonist that can sharpen interpretation of baroreflex, vascular, and cardiomyocyte assays. This article distinguishes receptor pharmacology from angiotensin II-driven hypertension and translates sex-specific telemetry findings into better experimental decisions.
-
PYR-41 and IRF7: Reading Ubiquitin Signals
2026-09-02
PYR-41, an inhibitor of Ubiquitin-Activating Enzyme E1, offers a useful perturbation point for separating ubiquitin-dependent protein turnover from antiviral transcriptional control. This article connects the IBDV–VP3–IRF7 mechanism to rigorous assay design while defining the limits of extrapolating PYR-41 data across infection and inflammation models.
-
Rex Biosensor Maps Bacterial NADH/NAD+ Redox
2026-09-02
The reference study introduced a genetically encoded, ratiometric NADH/NAD+ biosensor based on the redox-responsive bacterial transcription factor Rex. By tuning Rex and its operator sequence, the authors enabled noninvasive measurements, identified respiratory-chain mutants with elevated redox signals, and demonstrated enrichment of rare high-NADH cells in a pooled screen.
-
v-Agatoxin-IVA Reveals N-Type Ca Blockade
2026-09-01
Sidach and Mintz reexamined the assumption that v-Agatoxin-IVA is a highly selective P-type calcium-channel blocker. Using whole-cell recordings from rat subthalamic and sympathetic neurons, they showed that higher toxin concentrations can produce low-affinity, voltage-dependent N-type channel blockade, limiting the toxin’s use as a Q-type channel discriminator.
-
AT-406 (SM-406): Reliable Apoptosis Assays
2026-09-01
A scenario-based guide to using AT-406 (SM-406), SKU A3019, in cell viability, apoptosis, and combination-treatment experiments. It connects mechanism, solvent handling, dose selection, orthogonal readouts, and evidence-aware supplier evaluation for cancer research workflows.